坏死性下垂
雷公藤甲素
上睑下垂
癌细胞
程序性细胞死亡
癌症
癌症研究
医学
免疫原性细胞死亡
放射治疗
细胞凋亡
免疫学
药理学
生物
内科学
生物化学
作者
Ali Hamid AbdulHussein,Muataz Mohammed Al‐Taee,Zahra Abdul Radih,Dhuha Salman Aljuboory,Zainab Qasim Mohammed,Tabarak Sami Hashesh,Yassine Riadi,Salema K. Hadrawi,Masoud Najafi
出处
期刊:Biofactors
[Wiley]
日期:2023-03-06
卷期号:49 (4): 718-735
被引量:10
摘要
Abstract Drug resistance is a hot topic issue in cancer research and therapy. Although cancer therapy including radiotherapy and anti‐cancer drugs can kill malignant cells within the tumor, cancer cells can develop a wide range of mechanisms to resist the toxic effects of anti‐cancer agents. Cancer cells may provide some mechanisms to resist oxidative stress and escape from apoptosis and attack by the immune system. Furthermore, cancer cells may resist senescence, pyroptosis, ferroptosis, necroptosis, and autophagic cell death by modulating several critical genes. The development of these mechanisms leads to resistance to anti‐cancer drugs and also radiotherapy. Resistance to therapy can increase mortality and reduce survival following cancer therapy. Thus, overcoming mechanisms of resistance to cell death in malignant cells can facilitate tumor elimination and increase the efficiency of anti‐cancer therapy. Natural‐derived molecules are intriguing agents that may be suggested to be used as an adjuvant in combination with other anticancer drugs or radiotherapy to sensitize cancer cells to therapy with at least side effects. This paper aims to review the potential of triptolide for inducing various types of cell death in cancer cells. We review the induction or resistance to different cell death mechanisms such as apoptosis, autophagic cell death, senescence, pyroptosis, ferroptosis, and necrosis following the administration of triptolide. We also review the safety and future perspectives for triptolide and its derivatives in experimental and human studies. The anticancer potential of triptolide and its derivatives may make them effective adjuvants for enhancing tumor suppression in combination with anticancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI